Agilent Technologies Inc. (A) Wednesday said that its MMR IHC Panel pharmDx, developed in partnership with Bristol Myers Squibb, has received approval from the U.S.Food and Drug Administration (FDA) as a companion diagnostic test for colorectal cancer.
This test helps to identify mismatch repair deficient colorectal cancer patients who are eligible for treatment with Bristol Myers Squibb's Opdivo alone or in combination with Yervoy.
"Our new CDx product offers healthcare providers an additional tool to identify mismatch repair deficiency in patients, complementing existing options and enhancing the ability to tailor immunotherapy treatments," said Nina Green, vice-president and general manager of Agilent's Clinical Diagnostics Division.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.